Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan, Traci M Blonquist, Andrew M Brunner, Gabriela S Hobbs, Hanno R Hock, Steven L McAfee, Jenna A Moran, Meghan K Bergeron, Julia E Foster, Christina Bertoli, Kristin McGregor, Christine Connolly, Tanya T Behnan, Tina T Som, Aura Y Ramos, Megan K Vartanian, Jennifer Lombardi Story, Donna S Neuberg, Amir T Fathi
{"title":"Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.","authors":"Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan, Traci M Blonquist, Andrew M Brunner, Gabriela S Hobbs, Hanno R Hock, Steven L McAfee, Jenna A Moran, Meghan K Bergeron, Julia E Foster, Christina Bertoli, Kristin McGregor, Christine Connolly, Tanya T Behnan, Tina T Som, Aura Y Ramos, Megan K Vartanian, Jennifer Lombardi Story, Donna S Neuberg, Amir T Fathi","doi":"10.1080/10428194.2025.2476655","DOIUrl":null,"url":null,"abstract":"<p><p>Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical models. Adults >60 years of age with newly diagnosed AML were enrolled. Induction consisted of cytarabine and daunorubicin with ixazomib provided on days 2, 5, 9, and 12. In a second phase, induction was followed by consolidation with cytarabine and ixazomib on days 2, 5, 9, and 12. Among the 39 patients enrolled, there was 1 DLT, grade 4 thrombocytopenia. There were no grade 3 or 4 neurotoxicity events attributable to ixazomib. The composite remission rate (CCR) was 69%. The median OS for the 39 patients was 38.5 months. The highest dose level (3 mg) of ixazomib planned for induction and consolidation in this trial has been reached safely and is the RP2D for both.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2476655","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical models. Adults >60 years of age with newly diagnosed AML were enrolled. Induction consisted of cytarabine and daunorubicin with ixazomib provided on days 2, 5, 9, and 12. In a second phase, induction was followed by consolidation with cytarabine and ixazomib on days 2, 5, 9, and 12. Among the 39 patients enrolled, there was 1 DLT, grade 4 thrombocytopenia. There were no grade 3 or 4 neurotoxicity events attributable to ixazomib. The composite remission rate (CCR) was 69%. The median OS for the 39 patients was 38.5 months. The highest dose level (3 mg) of ixazomib planned for induction and consolidation in this trial has been reached safely and is the RP2D for both.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
